Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02811302 · ClinicalTrials.gov registry record · NA
PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY
A NA study, sponsored by Medtronic - MITG.
- Completed
- Registry status
- NA
- Development phase
- 1,495
- Enrollment target
NCT02811302 is a NA study that has completed, run by Medtronic - MITG. The registered enrollment target is 1,495 participants.
The verdict
NCT02811302, a NA study, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,495 participants
- Enrollment target
Study Summary
PRODIGY is a prospective, multi-center, post-market, international cohort study. The primary objective of this study is to derive a score to identify subjects at risk to have respiratory depression (RD) episodes in patients undergoing opioid therapy in the hospital ward and monitored by capnography. The score will be derived by using subjects within the derivation cohort and internally validated using subjects within the validation cohort. The primary endpoint used to derive the score will be the occurrence of RD episodes derived by Capnostream 20p device memory data combined with clinical data and validated by an independent Clinical Endpoint Committee (CEC) during the study course.
Interventions
- DEVICE Capnostream Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,495 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2018-05-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02811302
The ClinicalTrials.gov registry entry for NCT02811302 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,495 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Capnostream Monitor is the first listed.
NCT02811302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02811302 about?
NCT02811302 is a clinical study titled "PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY". PRODIGY is a prospective, multi-center, post-market, international cohort study. The primary objective of this study is to derive a score to identify subjects at risk to have respiratory depression (RD) episodes in patients undergoing opioid therapy in the hospital ward and monitored by capnography....
What is the current status of trial NCT02811302?
This trial is currently completed. It is a NA study. The enrollment target is 1,495 participants. The study started on 2017-04-07. Estimated completion is 2018-05-07.
What interventions are being tested in trial NCT02811302?
The interventions under investigation include: Capnostream Monitor (DEVICE).
Who is sponsoring clinical trial NCT02811302?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.